Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. (STOK) Annual Report Summary: Fiscal Year Ended December 31, 2023

Stoke Therapeutics (STOK), a clinical-stage biotechnology company listed on Nasdaq, closed out 2023 focused on developing novel RNA-based medicines for severe genetic diseases. This summary provides a concise overview of Stoke's operations, financial performance, and future outlook for the fiscal year ended December 31, 2023, based on its recent 10-K filing. As a "smaller reporting company," Stoke provides less detailed disclosures than larger public companies, which can potentially increase investment risk and volatility.

Business Overview (Core Business and Clinical Progress): Stoke focuses on its unique TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform aims to boost protein production from healthy genes, addressing diseases caused by insufficient protein. Its lead candidate, zorevunersen (STK-001), an RNA-based medicine, is in clinical trials for Dravet syndrome, a severe and progressive genetic epilepsy.

In 2023, Stoke advanced zorevunersen through its Phase 1/2a MONARCH study and began the SWALLOWTAIL long-term extension study. Positive interim data from these trials showed a favorable safety profile and significantly reduced seizure frequency for Dravet syndrome patients, suggesting its potential as a disease-modifying therapy. Stoke is actively preparing for a pivotal Phase 3 study and is discussing plans with regulatory bodies.

Competitive Position: The rare disease biotechnology industry is highly competitive. Stoke competes with other pharmaceutical and biotech companies developing or already offering treatments for Dravet syndrome and other genetic epilepsies. Competitors include companies with approved therapies, those in clinical development, and those using different treatment approaches.

Stoke's competitive edge lies in its proprietary TANGO platform and zorevunersen's unique mechanism of action. Zorevunersen aims to treat the underlying genetic cause of Dravet syndrome by boosting protein production. Successfully developing, gaining regulatory approval for, and commercializing zorevunersen with a differentiated clinical profile (efficacy, safety, and convenience) will be crucial for Stoke's competitive success. Its intellectual property protecting the platform and candidates also forms a key competitive strategy.

Financial Performance: In 2023, Stoke reported total revenue of approximately $15.0 million, mainly from its collaboration with Biogen. This marks a decrease from $20.0 million in the prior year, due to the timing of milestone payments. Stoke reported a net loss of $120.0 million, up from $105.0 million last year. This increase stemmed from higher research and development (R&D) expenses as zorevunersen progressed through clinical trials. R&D expenses were approximately $95.0 million, while general and administrative (G&A) expenses were around $30.0 million.

Management's Discussion and Analysis (MD&A) Highlights: Management's discussion highlighted the company's financial condition and operating results. The net loss grew primarily due to increased R&D expenses, reflecting substantial investment in advancing zorevunersen (STK-001) through its clinical program, including the MONARCH study and the launch of the SWALLOWTAIL long-term extension study. Revenue, mainly from the Biogen collaboration, decreased year-over-year because of milestone payment timing.

Stoke emphasized its strong cash position, projected to fund operations into the first half of 2026. This highlights the importance of careful capital management and the potential need for future financing to support ongoing clinical trials and commercialization. Management also noted the Biogen collaboration as a key strategic element, providing non-dilutive funding and validating the TANGO platform.

Financial Health: Stoke ended 2023 with approximately $250.0 million in cash, cash equivalents, and marketable securities. This strong cash position funds ongoing clinical development. Management estimates these resources will fund operations into the first half of 2026. The company has no significant debt, maintaining a healthy balance sheet for a development-stage biotech. However, future capital raises, possibly through equity offerings, will likely be necessary to complete pivotal trials and prepare for potential commercialization, which could dilute shareholder value.

Strategic Collaborations: Stoke collaborates strategically with Biogen International GmbH to develop RNA-based medicines for a specific neurological target. Under this agreement, Stoke received an upfront payment and can earn up to $500.0 million in potential milestone payments for achieving development, regulatory, and commercial goals, plus tiered royalties on future sales. This collaboration provides non-dilutive funding and validates Stoke's TANGO platform.

Risk Factors: Investing in Stoke Therapeutics involves significant risks, common in the biotechnology sector. Stoke's success heavily depends on successfully developing, gaining regulatory approval for, and commercializing zorevunersen, which is not guaranteed. Clinical trials are expensive, time-consuming, and may not yield positive results or meet regulatory endpoints. Delays or failures in clinical trials, or an inability to obtain regulatory approvals, would severely impact the company's prospects and stock price.

Other critical risks include:

• Competition: The Dravet syndrome market is competitive. Stoke must differentiate zorevunersen to succeed.
• Intellectual Property: Maintaining and enforcing patent protection for its TANGO platform and product candidates is vital.
• Capital Requirements: Stoke needs substantial additional funding to advance its pipeline, which may not be available on favorable terms.
• Reliance on Third Parties: The company relies on contract research organizations (CROs) for clinical trials and contract manufacturing organizations (CMOs) for drug supply.

Future Outlook: For 2024 and beyond, Stoke's primary goal is to advance zorevunersen toward a pivotal Phase 3 clinical trial for Dravet syndrome. Key anticipated milestones include:

• Providing further updates from the MONARCH and SWALLOWTAIL studies.
• Finalizing the design and initiating a pivotal Phase 3 study for zorevunersen following regulatory discussions.
• Advancing its preclinical pipeline programs, including potential candidates for other genetic epilepsies and neurological disorders.
• Potentially achieving additional milestones under the Biogen collaboration.

Stoke's future hinges on its ability to execute its clinical development strategy, secure regulatory approvals, and effectively manage financial resources to bring innovative therapies to patients.